NewsPress ReleasesVerseau Therapeutics Appoints John Edwards as Chief Executive Officer May 26, 2021Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies October 21, 20193SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies February 11, 2019Presentations and PublicationsVerseau Presents Data to Support Importance of Targeting PSGL-1 to Suppress Tumor Growth at Society for Immunotherapy of Cancer’s (SITC) November 9, 2020
